Short Interest in Mainz Biomed NV (NASDAQ:MYNZ) Decreases By 31.6%

Mainz Biomed NV (NASDAQ:MYNZ) was the recipient of a large decrease in short interest during the month of December. As of December 15th, there was short interest totaling 212,454 shares, a decrease of 31.6% from the November 30th total of 310,409 shares. Currently, 2.5% of the shares of the stock are sold short. Based on an average trading volume of 133,918 shares, the short-interest ratio is currently 1.6 days. Based on an average trading volume of 133,918 shares, the short-interest ratio is currently 1.6 days. Currently, 2.5% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

Several analysts have issued reports on the stock. Wall Street Zen raised shares of Mainz Biomed to a “hold” rating in a report on Saturday. Weiss Ratings reaffirmed a “sell (e)” rating on shares of Mainz Biomed in a research note on Monday, December 22nd. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $14.00.

Mainz Biomed Price Performance

MYNZ traded down $0.05 during trading on Tuesday, hitting $1.16. The company’s stock had a trading volume of 290,177 shares, compared to its average volume of 187,265. Mainz Biomed has a twelve month low of $0.92 and a twelve month high of $8.20. The firm’s 50 day moving average price is $1.24 and its 200-day moving average price is $1.50. The company has a current ratio of 0.52, a quick ratio of 0.43 and a debt-to-equity ratio of 0.44.

Mainz Biomed (NASDAQ:MYNZ) last released its earnings results on Friday, September 26th. The company reported ($1.32) earnings per share for the quarter. The company had revenue of $0.14 million during the quarter. As a group, equities research analysts anticipate that Mainz Biomed will post -23.6 earnings per share for the current year.

Hedge Funds Weigh In On Mainz Biomed

A hedge fund recently raised its stake in Mainz Biomed stock. Armistice Capital LLC grew its position in shares of Mainz Biomed NV (NASDAQ:MYNZ) by 45.0% during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 285,000 shares of the company’s stock after purchasing an additional 88,400 shares during the period. Armistice Capital LLC owned approximately 6.23% of Mainz Biomed worth $402,000 as of its most recent SEC filing.

Mainz Biomed Company Profile

Mainz Biomed AG is a molecular diagnostics company headquartered in Mainz, Germany, specializing in epigenetics-based tests for the early detection of cancer. The company develops proprietary assays that analyze DNA methylation patterns and other epigenetic biomarkers to identify malignancies at a stage when treatment outcomes are most favorable. Mainz Biomed’s technology platform is designed to offer non-invasive, easy-to-use screening solutions that can be deployed both in laboratory settings and at point of care.

The company’s flagship product, ColoAlert®, is a stool-based colorectal cancer screening test that combines DNA methylation markers with bacterial gene targets to improve sensitivity and specificity for detecting advanced adenomas and early-stage colorectal cancer.